Contact
Please use this form to send email to PR contact of this press release:
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
TO:
Please use this form to send email to PR contact of this press release:
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
TO: